Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

Post PCI FFR Reduces MACE

Original Title: Utilizing Post-Intervention Fractional Flow Reserve to Optimize Acute Results and the Relationship to Long-Term Outcomes

Reference: Shiv K. Agarwal, et al. JACC Cardiovascular Intervention 2016;9:1022-31

 

Courtesy of Dr. Carlos Fava.

 

FFR post PCIFractional flow reserve has shown benefits and it is considered the gold standard to assess intermediate lesions (Class IA), but its use post PCI has not been evaluated yet.

574 patients with 664 lesions were analyzed; 45% had a history of diabetes, 48% multivessel disease and 45% diffuse disease.

Previous obstruction degree by quantitative angiography was 73±15%, 96% with FFR ≤0.80 and 73% FFR ≤0.75, regardless adenosine administration technique.

After PCI with angiographically satisfactory results, 21% (143 lesions) presented a suboptimal FFR ≤0.80 (0.75±0.05). After a second intervention to this group (post balloon dilation, subsequent stent implantation, or IVUS or OCT lesion assessment) FFR increased to 0.87±0.06 (p<0.0001). 9% continued with suboptimal FFR.

This was associated to longer procedural and fluoroscopy time, but not with more contrast.

Follow up was at 31 months with 19% of patients presenting some event (62 death by any cause, 12 MI, and 60 revascularizations).

MACE predictors were ACS, diffuse lesions and ≤0.86 final FFR.

In ROC curve analyzis, final FFR cutoff value predictor of MACE was ≤0.86 (23% vs. 17% p=0.02), for death ≤0.87 (13.5% vs. 9% p=0.03) and TVR ≤0.85 (12% vs. 8% p=0.03).

Conclusion

Post PCI FFR reclassifies 20% of PCI with satisfactory results, requiring more intervention to achieve complete functional revascularization at the time of index procedure. Post PCI FFR is an independent predictor of long term evolution.

Editorial Comment

This analyzis shows the concept of PCI “Functional Optimization”, because 20% of patients present ischemia after a satisfactory angiography.

Ideally, we should identify the groups that could benefit from this strategy in order not to unnecessarily prolong procedures and to save costs.

Courtesy of Dr. Carlos Fava. Favaloro Foundation, Buenos Aires, Argentina.

We value your opinion. You are more than welcome to leave your comments, thoughts, questions or any ideas here below.

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...

EuroPCR 2026 | LANDMARK Trial: Two-Year Results Showed Comparable Efficacy Between Myval and Contemporary TAVI Valves

The LANDMARK trial presentation, delivered by Prof. Patrick W. Serruys at EuroPCR 2026, detailed the two-year clinical outcomes of contemporary transcatheter aortic valve implantation...